Skip to main content
. 2023 Sep 20;17(1):131–148. doi: 10.1016/j.jcmgh.2023.09.005

Table 2.

Clinical Characteristics of Pediatric Patients with Inflammatory Bowel Disease in the DYNAMIC Cohort

Diagnosis, n (%)
 Crohn’s disease 55 (79.71)
 Ulcerative colitis 8 (11.59)
 IBD-U 6 (8.70)
Median age at diagnosis, y (range) 12.97 (7.52–17.74)
Years since diagnosis at enrollment, median (range) 0.02 (0.00–9.66)
Crohn’s disease–Paris Classification lower GI tract location, n (%)
 Ileal L1 12 (22.64)
 Colonic L2 9 (16.98)
 IIeocolonic L3 30 (56.60)
 None 2 (3.77)
Crohn’s disease–Paris Classification phenotype, n (%)
 Inflammatory B1 48 (87.27)
 Stricturing B2 5 (9.09)
 Stricturing/penetrating B2/B3 2 (3.64)
Ulcerative colitis extent/IBD-U, n (%)
 E2 left-sided colitis 5 (41.67)
 E4 pancolitis 7 (58.33)
Patients initiating therapy at enrollment, n (%) 31 (44.93)
Current medication for IBD, n (%)
 Mesalamine 26 (37.68)
 Biologic 44 (63.77)
 Steroids 8 (11.59)
 Immunomodulators 15 (21.74)
Calprotectin level, ug/dL, median (IQR)
 Baseline 689 (180–1702.5)
 Week 4 421 (94–998)
 Week 8 300 (48–809)
Disease activity index, median (range)
 Pediatric Crohn’s Disease Activity Index
 Baseline 30 (0–50)
 Week 4 7.5 (0–37.5)
 Week 8 7.5 (0–55)
 Pediatric Ulcerative Colitis Activity Index
 Baseline 45 (0–75)
 Week 4 10 (0–40)
 Week 8 10 (0–45)

GI, gastrointestinal; IQR, interquartile range.